{"id":"reduced-dose-intensity-of-io","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (reduced incidence expected vs. standard dosing)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4574125","moleculeType":"Unknown","molecularWeight":"212.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a dosing strategy rather than a novel drug, where standard immunotherapy agents (such as checkpoint inhibitors) are administered at lower doses or extended intervals. The approach seeks to optimize the benefit-risk profile by reducing cumulative exposure to immune-activating agents, thereby lowering the incidence and severity of immune-related adverse events while preserving therapeutic activity.","oneSentence":"Reduced dose intensity of immunotherapy (IO) aims to maintain anti-tumor efficacy while decreasing treatment-related toxicity through lower or less frequent dosing schedules.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:41.354Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer treatment optimization via dose-reduced immunotherapy regimens (specific tumor types under investigation in UNICANCER phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT05078047","phase":"PHASE3","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-03-08","conditions":"Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer","enrollment":646}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Reduced dose intensity of IO","genericName":"Reduced dose intensity of IO","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reduced dose intensity of immunotherapy (IO) aims to maintain anti-tumor efficacy while decreasing treatment-related toxicity through lower or less frequent dosing schedules. Used for Cancer treatment optimization via dose-reduced immunotherapy regimens (specific tumor types under investigation in UNICANCER phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}